We are live on ! Find out more
ALIM

Alimera Sciences
ALIM

Delisted

ALIM was delisted on the 13th of September, 2024.

Back to rankings

39 hedge funds and large institutions have $38.2M invested in Alimera Sciences in 2019 Q1 according to their latest regulatory filings, with 6 funds opening new positions, 9 increasing their positions, 9 reducing their positions, and 6 closing their positions.

New
Increased
Maintained
Reduced
Closed

49% more capital invested

Capital invested by funds: $25.6M → $38.2M (+$12.6M)

0% more funds holding

Funds holding: 39 → 39 (0)

0% more first-time investments, than exits

New positions opened: 6 | Existing positions closed: 6

0% more repeat investments, than reductions

Existing positions increased: 9 | Existing positions reduced: 9

Holders
39
Holders Change
–
Holders Change %
0%
% of All Funds
0.84%
Holding in Top 10
1
Holding in Top 10 Change
+1
Holding in Top 10 Change %
% of All Funds
0.02%
New
6
Increased
9
Reduced
9
Closed
6
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
RA
Royce & Associates
New York
+$256K
2
Renaissance Technologies
Renaissance Technologies
New York
+$191K
3
BCM
Bridgeway Capital Management
Texas
+$101K
4
Citadel Advisors
Citadel Advisors
Florida
+$92.6K
5
CPA
Columbia Pacific Advisors
Washington
+$51.2K

Top Sellers

Rank Fund Capital Flow
1
O
OrbiMed
New York
-$180K
2
BRF
B. Riley Financial
California
-$147K
3
SCM
Stonepine Capital Management
Oregon
-$65.1K
4
TRCT
Tower Research Capital (TRC)
New York
-$24.9K
5
VF
Virtu Financial
New York
-$22K
Name Holding Trade Value Shares
Change 		Change in
Stake
Cambridge Investment Research Advisors
26
Cambridge Investment Research Advisors
Iowa
$19K -$5.78K -380 -24%
MCM
27
Mainstay Capital Management
Michigan
$16K – – –
FIM
28
Freedom Investment Management
Connecticut
$13K +$12.5K +820 New
SCM
29
Southport Capital Management
Tennessee
$12K – – –
SWM
30
SeaCrest Wealth Management
New York
$11K – – –
SRC
31
Shufro Rose & Co
New York
$11K – – –
S
32
SignatureFD
Georgia
$2K – – –
PCM
33
Prelude Capital Management
New York
$1K -$137 -9 -11%
Bank of Montreal
34
Bank of Montreal
Ontario, Canada
$1K – – –
CFGS
35
Concourse Financial Group Securities
Alabama
$1K – – –
LTFS
36
Ladenburg Thalmann Financial Services
Florida
$1K – – –
Barclays
37
Barclays
United Kingdom
$1K +$548 +36 +600%
BNP Paribas Financial Markets
38
BNP Paribas Financial Markets
France
$5 – – –
O
39
OrbiMed
New York
– -$180K -16,667 Closed
VF
40
Virtu Financial
New York
– -$22K -2,075 Closed
TRCT
41
Tower Research Capital (TRC)
New York
– -$24.9K -1,634 -99%
Invesco
42
Invesco
Georgia
– -$11K -1,008 Closed
Wells Fargo
43
Wells Fargo
California
– -$10K -900 Closed
SIAG
44
Signet Investment Advisory Group
Rhode Island
– -$5K -500 Closed
UBS Group
45
UBS Group
Switzerland
– -$2K -231 Closed
1
2

ALIM Hedge Fund Activity: Q1 2019 in Review

39 of the 4,621 institutional investors tracked by Wall St. Rank reported a position in Alimera Sciences (ALIM) for Q1 2019, worth a combined $38.2M — up 49% from $25.6M a quarter earlier.

Fund positioning in ALIM was balanced in Q1 2019: 6 funds opened new positions, 6 closed out, 9 added to existing stakes and 9 trimmed.

The largest buyer was Royce & Associates, adding an estimated $256K. The largest seller was OrbiMed, exiting entirely with an estimated $180K sold.

  • 39 institutional investors held Alimera Sciences (ALIM) as of Q1 2019, unchanged from Q4 2018.
  • Funds reported $38.2M of Alimera Sciences stock for Q1 2019, up 49% quarter-over-quarter.
  • 6 funds opened new Alimera Sciences positions in Q1 2019 and 6 closed out, a net change of 0 holders.
  • The largest Alimera Sciences buyer in Q1 2019 was Royce & Associates, an estimated $256K added.
  • The largest Alimera Sciences seller in Q1 2019 was OrbiMed, an estimated $180K sold.

Based on aggregated 13F filings for Q1 2019.